Investigación in vitro del metabolismo y la toxicidad de fármacos en el hombre by Gómez Lechón, María José & Donato, M. T.
5An. R. Acad. Nac. Farm., 2007, 73: 5-26
Revisión
* Corresponding author: María José Gómez-Lechón.
Unidad de Hepatología Experimental, Centro de Investigación. Hospital Universita-
rio La Fe, Avda. Campanar, 21, E-46009-Valencia, Spain.
e-mail: gomez_mjo@gva.es; Telf.: +34 96 197 30 48; Fax: +34 96 197 30 18.
Abbreviations:
ADMET: Absorption-Distribution-Metabolism-Excretion-Toxicity.
EMEA: European Agency for the Evaluation of Medicinal products.
FDA: Food and Drug Administration.
P450: Cytochrome P450 system.
In vitro investigation of drug metabolism
and toxicity in man
Recibido el 1 de febrero de 2007
MARÍA JOSÉ GÓMEZ-LECHÓN A * and
MARÍA TERESA DONATO A, B
A) Unidad de Hepatología Experimental, Centro de Investigación,
Hospital La Fe, Avda. Campanar, 21, 46009-Valencia, Spain.
B) Departamento de Bioquímica y Biología Molecular,
Facultad de Medicina, Universidad de Valencia,
Avda. Blasco Ibáñez 15, 46010-Valencia, Spain
ABSTRACT
The pharmaceutical industry is committed to marketing safer drugs with fewer
side effects, predictable pharmacokinetic properties and quantifiable drug-drug
interactions. Drug metabolism is a major determinant of drug clearance and
interindividual pharmacokinetic differences, and an indirect determinant of the
clinical efficacy and toxicity of drugs. From a commercial perspective, it is desirable
that poorly behaved compounds are removed early in the discovery phase rather
than during the more costly drug development phases. As a consequence, over the
past decade, in vitro-based strategies in lead optimization screening in conjunction
with ADMET screening studies have been incorporated earlier in the drug discovery
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phase. At present, the use of human in vitro hepatic models at early preclinical
stages means that the process of selecting drug candidates is becoming much more
rational. Several in vitro tools are available to address key issues at the earliest
stages of drug development for a better candidate selection and hepatotoxicity risk
assessment.
Key words: Cytochrome P450.—Drug metabolism.—Drug-drug interaction.—
Hepatotoxicity.—Human hepatocytes.—Microsomes.
RESUMEN
Investigación in vitro del metabolismo y la toxicidad de fármacos
en el hombre
El interés de la industria farmacéutica es incrementar la seguridad de los nue-
vos fármacos, disminuir sus efectos secundarios, conocer sus propiedades farma-
cocinéticas e identificar las posibles interacciones fármaco-fármaco. El metabolis-
mo de los fármacos es un factor determinante en su aclaramiento, es responsable
de la variabilidad interindividual de la farmacocinética y en consecuencia, de la
variación en el efecto farmacológico y la toxicidad. Desde la óptica comercial, lo
deseable es que los fármacos con propiedades no adecuadas sean descartados en
las fases más tempranas del desarrollo, y no en las fases posteriores con mayor
coste económico. Como consecuencia de esto, en las últimas décadas se han incor-
porado estrategias basadas en modelos in vitro en combinación con estudios de
ADMET, para la selección de nuevos fármacos cabeza de serie durante fases muy
tempranas del desarrollo. Actualmente, la utilización de modelos hepáticos huma-
nos in vitro en las fases preclínicas supone un proceso de selección de nuevas
moléculas candidatas a fármacos mucho más racional. Existen varios modelos in
vitro para abordar estas cuestiones en las etapas tempranas del desarrollo de fár-
macos para optimizar la selección de moléculas candidatas y la evaluación del
riesgo de hepatotoxicidad.
Palabras clave: Citocromo P450.—Metabolismo de fármacos.—Interacción fár-
maco-fárrmaco.—Hepatotoxicidad.—Hepatocitos humanos.—Microsomas.
INTRODUCTION
Drugs and other xenobiotics usually have a low solubility in
aqueous systems and require biotransformation to metabolites that
are more hydrophilic and more readily eliminated. Typically, liver
drug metabolism occurs in two phases: Phase I and Phase II. Phase
I of biotransformation is the oxidative pathway in which the
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compound undergoes oxidation to a more polar substance.
Cytochrome P-450 (P450)-depending monooxygenases and flavin
monooxygenases, are major role players in the oxidative metabolism
of xenobiotics and endogenous compounds. This process is followed
by the Phase II reactions in which metabolites are further conjugated
by hepatocytes with endogenous molecules by glucoronidation,
sulfation, methylation, acetylation and mercapture formation,
rendering derivatives that are much more soluble, thus facilitating
their elimination (1-3). Biotransformation reactions generally follow
a detoxification process rendering metabolites inactive. Nevertheless,
many drug intermediary products generated during metabolism
are highly reactive and toxic, causing hepatotoxicity (4-6).
Metabolism is the major determinant of drug clearance and
interindividual pharmacokinetic differences, and the indirectly
determinant of the clinical efficacy and toxicity of drugs. Many
potential drug candidates are rejected in drug discovery given the
undesirable pharmacokinetics that can result in an inadequate
concentration of the drug at the site of action and/or great variations
in clinical response and adverse effects.
Drug regulatory agencies, such as the Food and Drug
Administration (FDA) and the European Agency for the Evaluation
of Medicinal Products (EMEA) (7), have issued different guidelines
to enhance the importance of ADME studies in the drug development
process. The pharmaceutical industry is required to market safer
drugs with fewer side effects, predictable pharmacokinetic properties
and quantifiable drug-drug interactions. Therefore, companies are
increasingly interested in optimizing these properties during early
drug development phases (Figure 1). Rapid biotransformation,
resulting in a short exposure to the pharmacologically active parent
compound and the formation of active or toxic metabolites, is not
usually welcomed. Alternatively, an extremely stable drug may pose
a potential problem of drug-drug interactions and toxicity. Medicinal
chemists are primarily concerned in designing molecules that will
not only offer the desired activity, but suitable potency and duration
of action which are influenced by pharmacokinetic properties.
Consequently over the past decade, in vitro-based strategies in lead
optimization screening in conjunction with ADMET screening studies
have been incorporated earlier in the drug discovery phase (8, 9).
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FIGURE 1. Drug development process depicting the different types of ADME
studies that could be performed at the various stages. Investigational New
Drug (IND). New Drug Application (NDA).
KEY ISSUES TO BE ADDRESSED AT EARLY STAGES OF
DRUG DEVELOPMENT
After intake, drugs are absorbed and distributed among the
tissues and body fluids and then eliminated or cleared, mainly by the
liver and kidneys. Therefore, the development of a new drug requires
an exhaustive characterization of not only its pharmacological
activity, but also knowledge of major enzymes involved in the
metabolite formation, and the potential enzyme-inhibiting or
enzyme-inducing properties of the drug. Therefore, over the last
decade, in vitro-based strategies in lead optimization screening
combined with ADMET screening studies have consequently been
incorporated earlier in the drug discovery phase (10).
Several metabolic key issues should be addressed at very early
stages of drug development for a better selection of the safest and
most effective drug candidates (Figure 2):
a) Drug metabolic stability and metabolic profile.
b) Metabolite identification and structure clarification.
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c) Prediction of in vivo pharmacokinetic parameters from in
vitro data.
d) Identification of the P450 enzymes involved in drug
metabolism.
e) Interspecies comparison of the metabolic profile of a drug to
select the animal. species closest to man for preclinical
studies.
f) Drug-drug interactions due to enzyme induction/inhibition.
g) Drug toxicity associated with drug metabolism.
FIGURE 2. Major applications of in vitro hepatic models during the
development of new drugs.
DRUG METABOLIC STABILITY AND METABOLIC PROFILE
AND METABOLITE IDENTIFICATION
Using in vitro methods enables us to determine and predict the
metabolic stability of NCEs, which can be an important contributor
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for a good pharmacokinetic profile as well as a risk for drug-drug
interactions. Metabolic stability is defined as the susceptibility of a
chemical compound to biotransformation, and is expressed as in
vitro half-life (t(1/2)) and intrinsic clearance (CL(int)). Based on these
values, in vivo pharmacokinetic parameters, such as bioavailability
and in vivo half-life, can be calculated when other data concerning
the volume of distribution and fraction absorbed are available (11).
Metabolic stability assays can be easily investigated by incubating
new chemicals with fully competent metabolic models and
performing sensitive chromatographic analysis (e.g. HPLC-MS/MS)
of the incubation mixtures (12). In the early phases of chemical
screening, metabolic rates are estimated by measurement of the
disappearance of the test compound as metabolites are usually
unknown. At advanced stages, formation of metabolites is also
analyzed. Human liver microsomes, hepatocytes, and cDNA-
expressed P450 enzymes are commonly used (Figure 2). A major
disadvantage of using recombinant models expressing a single
enzyme for the study of metabolic stability of a drug is the lack of
other phase I and phase II enzymes. Human liver microsomes
contain high levels of P450s and other drug-metabolizing enzymes
(flavin monooxygenase, UDP-glucuronyltransferases, epoxide
hydrolase). The metabolites identified after a short incubation with
microsomes coincide with those reported as the major metabolites
in human in vivo studies (13). The major limitation of microsomes
is that they lack phase II cytosolic enzymes (glutathione S-
transferases, sulfotransferases, soluble epoxide hydrolases, alcohol
dehydrogenase, xanthine oxidase, etc.). Human hepatocytes represent
a more complete system with physiological levels of cofactors,
natural orientation for linked enzymes and intact membranes to
allow for the modeling of intracellular drug concentrations (14, 15)
(Figure 2). Moreover, the restricted accessibility of suitable human
liver samples has greatly hindered the widespread use of human
hepatocytes for drug metabolism studies. Recently, this scarcity has
been countered by the increasing availability of metabolically
competent cryopreserved human hepatocytes and by the use of
optimized metabolic assays in hepatocytes cultured in multiwell plate
formats (16, 17). Later in non clinical development, the ADME flow
chart focuses on metabolite profiling in different species and
metabolite identification. Significant metabolic interspecies
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differences between animals and man exist, not only because of the
different P450 enzymes expressed in man and other species, but also
because of their relative abundance (18-20). Therefore, metabolite
profiles in different animal models (i.e. microsomes or hepatocytes
from several species) are analyzed and compared with the human
profile toward a more astute selection of animal species for
subsequent pharmacokinetic or toxicological studies. As metabolites
may be inert, pharmacologically active or reactive, drug metabolite
profile evaluation and metabolite identification are essential to
design new safer drug candidates with improved ADME capabilities.
Incubating the drug candidate with recombinant P450s individually
expressed in various host systems can generate large amounts of
metabolites for chemical structure identification (Figure 2).
Analytically speaking, liquid chromatography tandem mass
spectrometry is the most widely used tool to identify metabolites
and determine both structure and metabolite profiles (21).
PREDICTION OF IN VIVO PHARMACOKINETIC
PARAMETERS FROM IN VITRO DATA
Human liver-derived models are invaluable tools in elucidating
the pharmacokinetic parameters of a drug candidate and the
selection of lead compounds with favorable properties during the
drug discovery and development process (22, 23). Clearance of a
drug from the body depends on the intrinsic ability of the organs,
such as liver and kidney, to metabolize and excrete. Systemic
clearance of a drug that is eliminated by hepatic metabolism is a
function of the hepatic blood flow and the intrinsic clearance of the
liver (CLint, in vivo), which is defined as the ability of the liver to
remove xenobiotics from the blood in the absence of other
confounding factors. Disease conditions of the liver or administration
of drugs that are inducers or inhibitors of P450 can therefore
influence systemic clearance. CLint, in vitro is a measure of enzyme
activity towards a drug which is not influenced by other physiological
determinants of liver clearance, such as hepatic blood flow or drug
binding to blood proteins (24). As with all clearance terms, it has
units of volume rate and acts as a proportionality constant to
describe the relationship between the metabolism rate of a drug and
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its concentration at the enzyme site. Two strategies underlying the
prediction of in vivo hepatic drug metabolism from in vitro data
have been defined (24, 25): the metabolite formation method, the
most widely used, and the more recently adopted substrate depletion
approach, where the intake of the parent drug is monitored over
time (25). From a biochemical point of view CLint, in vitro can be
considered in terms of the enzyme parameters of the Michaelis-
Menten equation (24, 26). Enzyme kinetics data must be obtained
under linear conditions with regard to the enzyme concentration
and incubation time, that is, the period when V0 is maintained. Once
CLint, in vitro is obtained from Michaelis-Menten constants (Km
and Vmax), reasonable estimates of in vivo hepatic clearance (CLint,
in vivo) can be obtained by using appropriate scaling factors and
modeling (24, 26, 27). Mathematical physiological models (well-
stirred, parallel tube, distributed and dispersion models) of hepatic
drug clearances, which use both anatomical and physiological data,
have been appraised in relation to their utility in predicting drug
removal by the liver (28-30).
IDENTIFICATION OF P450 ENZYMES INVOLVED IN DRUG
METABOLISM
Early identification of P450s responsible for the metabolism of
new molecules is important in drug discovery in order to minimize the
role of polymorphic enzymes leading to inter-individual variation and
potential drug-drug interactions. Pooled human liver microsomes are
the most frequently model used for this purpose (31, 32). A major
advantage of these in vitro systems is that P450 enzymes are present
in their physiological relative proportions and can interact with other
essential proteins required for P450-catalyzed oxidations (i.e. NADPH
cytochrome P450 reductase, cytochrome b5). By the use of selective
chemical inhibitors for individual P450s, the major metabolic
pathways for a new drug can be either readily demonstrated or ruled
out. The incubations in which the metabolism of the test drug is
reduced suggest the involvement of the P450 enzyme, whose activity
is affected by the inhibitor. One drawback that these assays present,
even when using potent inhibitors, is that it is not possible to
completely and selectively inhibit a single P450 activity.
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In recent years, recombinant human P450 systems have been
increasingly used for this purpose (Figure 2). Major limitations
inherent to recombinant models are that concentrations of P450
enzymes are far in excess of their relative amount in the human
liver, and that the secondary metabolism cannot be identified.
However, such disadvantages have not appeared to hinder the utility
of cDNA expressed enzymes to P450 reaction phenotyping.
Incubating the compound with each separate recombinant P450
provides information about the role of individual P450s in metabolite
formation (32, 33-37). However, the degree of involvement of a P450
in a particular reaction in vivo can neither be estimated nor can the
metabolic profile of a drug in man be anticipated. Different strategies
based on the combined use of in vitro models showing a full
contingent of P450 enzymes (i.e. human liver microsomes, primary
human hepatocytes) and P450 recombinant models have been
proposed to mathematically reconstruct the relative contribution of
each P450 enzyme in the metabolism of a given compound (35-39).
DRUG-DRUG INTERACTIONS DUE TO ENZYME
INDUCTION/INHIBITION
Pharmacokinetic interactions occur when the disposition (i.e.
absorption, distribution, metabolism and excretion) of a drug is
altered by another (40). One of the most important pharmacokinetic
factors that control drug action is the rate of metabolic
transformation. Hence, interactions that result in changes in the
rate of drug metabolism can be of great clinical significance. Many
drugs can inhibit, induce and alter relative amounts of different
P450 enzymes. A strong inhibition/induction of P450 activities
by a molecule is expected to seriously interfere with the metabolism
of other drugs administered simultaneously or subsequently. These
changes in in vivo metabolism rates can lead drug concentrations
to fall outside their therapeutic window, implication a serious risk
of drug-drug interactions. The high cost associated with drug
development programs has focused attention on predicting,
identifying and avoiding inhibitory potential early in the discovery
process. In vitro studies, which are generally inexpensive and readily
carried out, must serve as preliminary screenings to rule out the need
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of in vivo testing. The objective of in vitro screening of P450 inhibition
properties of drug candidates is to exclude potent inhibitors from
further development. P450 enzymes play a crucial role in the
metabolism of drugs and, therefore, P450 inhibition is the most
important mechanism for metabolic drug-drug interactions (41, 42).
Microsomes and cDNA-expressed enzymes are the preferred test
systems as they are more readily available than human hepatocytes
(Figure 2). Assays are based on the analysis of potential reductions
in the metabolism of an appropriate P450 probe substrate in the
presence of various concentrations of the tested compound (11, 13).
For the purpose of high throughput P450 inhibition screening, a
variety of strategies based on fluorescence, LC-MS and radiometry
approaches have been developed (43-45). Since several enzymes
may be involved in the metabolism of a compound, the use of
recombinant models expressing a single P450 may lead to an
overestimation of the inhibitory effect of a given drug (46). A major
limitation in making conclusive statements from assays in
microsomes or recombinant enzymes is that ultimately in vivo
metabolism is complicated by the role of processes missing in
subcellular models. Drug transport across membranes, further
metabolism by cytosolic enzymes, or binding to intracellular proteins
can be determinant in the actual concentration of the substrate and
inhibitor available to the enzyme (41, 47). Assays performed in intact
cells could be more predictive (47).
Drug-drug interactions can also occur as a consequence of P450
induction. Metabolic interactions due to enzyme induction are far
less frequent than those caused by inhibition; however, their
consequences can be clinically relevant. A drug with inductive
properties can accelerate its own metabolism or those of other
co-administered drugs, resulting in either therapeutic inefficacy or
in an exaggerated response. Screening of inducers cannot be done in
microsomes or recombinant models as it requires a cellular system
that is fully capable of expressing genes (Figure 2). Currently,
primary hepatocytes are still the unique in vitro model for global
examination of the inductive potential of drugs (14, 48, 49). After
24-72 h incubation with the test compound, P450 induction is
monitored as its increases in enzyme activity (using specific
substrates) or mRNA levels (by quantitative RT-PCR). Results are
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compared to those of untreated cells (Figure 3). Different
concentrations of the drug, covering a large range of concentrations,
are recommended to assess the inductive potential of a new chemical.
Generally, if a negative results from in vitro inhibition/induction
assays is obtained (no identified interaction), the study of potential
clinical interactions is not needed. In vitro experiments should
be conducted at similar concentrations to the relevant in vivo
concentration for the optimization of the clinical assays.
FIGURE 3. Effects of model inducers on P450 enzymes in cultured human
hepatocytes. After 24 h in culture, human hepatocytes were exposed to 2 μM
3-methylcholanthrene (MC), 1 mM phenobarbital (PB), 100 mM ethanol (ETH),
1 mM clofibric acid (CLF), 50 μM rifampicin (RIF), 1 μM dexamethasone (DEX),
50 μM omeprazole (OMP), or 1 nM ecteinascidin (ECT), and P450 activities
and mRNA levels were measured 48 h later. Activities were determined in
three different hepatocyte preparations by the use of selective substrates:
7-methoxyresorufin (CYP1A2) and testosterone (CYP3A4). Specific CYP mRNA
levels were quantified by quantitative RT-PCR in two different cultures.
Results are expressed as fold increases over corresponding activity or mRNA
values in controls (untreated cells).
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DRUG-INDUCED HEPATIC INJURY
Substances capable of producing liver damage and, more
specifically, hepatocyte damage are known as hepatotoxins. Intrinsic
hepatotoxins are substances that exert their effects in all individuals,
in a dose-dependent and hence predictable manner. These toxins
can interfere directly with cell metabolism (active hepatotoxins) (50)
or become toxic once they have been biotransformed (latent
hepatotoxins). Idiosyncratic hepatotoxicity, on the other hand, may
be the consequence of an abnormal metabolism of the drug by
susceptible individuals (metabolic idiosincrasy) or be elicited by an
immune-mediated hepatocyte injury (allergic hepatitis). The former
has a geno- or phenotypic basis that results in the over/under
expression of drug metabolizing enzymes, a different drug
metabolism pattern and eventually the abnormal production of a
toxic metabolite. This type of idiosyncratic toxicity is dose-dependent
in susceptible individuals. Idiosyncratic drug toxicity is a rare
human-specific event and therefore not detectable in experimental
animals and impossible to be studied in clinical trials (51). Some
xenobiotics are electrophilic in nature, and others are bioactivated
by the liver to highly reactive metabolites generally more toxic than
the parent compound, which is the key to many toxic phenomena
(50, 52, 53). To minimize these effects, hepatocytes have effective
defence mechanisms, and ultimately it is the balance between
bioactivation, detoxification and defence/repair mechanisms that
determines whether a compound will or will not elicit a toxic effect.
Figure 4 summarizes the molecular events that can be involved in
hepatocyte toxicity: 1) The impairment of the biochemical functions
of hepatocytes by the drug or by any of its stable metabolites is
the first possible mechanism of hepatotoxicity (52-54). 2) The
mitochondrion is a frequent target of hepatotoxic drugs and the
alteration of its function has immediate effects on the energetic
balance of cells (54). Depletion of ATP is, in fact, an early event in
the course of drug-induced toxicity that precedes the irreversible
stages of cell injury (56). 3) Lipid peroxidation. It is a free radical
process leading to the oxidative degradation of lipids that finally
may disrupt the structure and functionality of the cell membranes
(56). 4) Alteration of intracellular Ca2+ concentration. Intracellular
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calcium participates in many cellular functions and its levels should
be perfectly regulated to obtain a proper cell function. Many
substances can interfere in intracellular calcium homeostasis control,
thus leading to cell malfunction and death (50, 57). 5) Oxidative
stress is produced by compounds able to undergo repeated oxidation
and reduction cycles within the cell (58). This redox cycling causes
the continuous production of reactive oxygen species (e.g. superoxide
anion) and depletion of GSH and nicotinamide nucleotide pools,
with a concomitant increase in lipid peroxidation and intracellular
Ca2+ accumulation. Finally, biotransformation of xenobiotics can also
result in the formation of intermediates capable of covalently binding
to cell macromolecules (proteins, DNA and RNA) to form stable drug
adducts (58).
Cytotoxicity end-points (cell viability assays: MTT, neutral red
uptake tests, etc; cell membrane permeability alteration: enzyme
leakage; etc.) represent a first approach to assess hepatotoxicity, but
evaluation of these parameters alone may leave out of consideration
xenobiotics that impair cell function without causing cell death. This
may not be critical for the hepatocyte itself, but can be of toxicological
significance for the whole organism (59). By examining the effects on
hepatocyte-specific metabolism, it is possible to find out whether
relevant hepatic specific functions become altered by the presence of
a xenobiotic. Currently, several metabolic parameters, representative
of the liver’s most characteristic functions, should be evaluated,
namely, gluconeogenesis, glycogen metabolism, ureogenesis, plasma
protein synthesis, synthesis of VLDL, etc. In general, metabolic
parameters are more sensitive to the toxic effect of hepatotoxins than
cytotoxicity indicators (60). Concentrations to which cells are exposed
for cell metabolism studies should not cause perceptible cell death
(they should be up to the MNTC).
The ultimate goal of in vitro experiments is to generate the type
of scientific information needed to identify compounds that are
potentially toxic to man for which purpose not only the design of
experiments but also the interpretation of results are essential. Even
simple parameters for assessing cell toxicity have yielded promising
results when comparing in vitro effects with human toxicity as false
negatives are infrequent in compounds that are toxic without
biotransformation.
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FIGURE 4. Mechanisms of drug hepatotoxicity. Different mechanisms can be
involved in hepatocyte toxicity: Mitochondrion is a frequent target of hepatotoxic
drugs and the alteration of its function has immediate effects on the energetic
balance of cells (depletion of ATP). Lipid peroxidation, oxidative stress, alteration
of Ca2+ homeostasis and covalent binding to cell macromolecules are the molecular
mechanisms more frequently involved in the toxicity of xenobiotics.
The monitoring of gene expression of cells exposed to toxic
xenobiotics (toxicogenomics), has gained great popularity among
researchers (61-63). The ease with which thousands of genes can be
measured has led most of the scientists to register changes of as
many genes as possible with the hope that an in-depth biostatistical
analysis would reveal which of that gene were clearly linked to toxic
events. It is hoped that through a better understanding of cellular
mechanisms of toxicity, combined with mechanistically directed
toxicogenomic analysis, the accuracy and predictivity of in vitro
screening for toxicants could be greatly improved.
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VARIABILITY OF DRUG METABOLIC CAPABILITY
IN HUMANS
Variability of drug metabolism rates is a consistent observation
in human populations. Considerable differences can be observed
among «extreme» individuals. Progressive advances in the knowledge
of metabolic routes and enzymes responsible for drug
biotransformation have contributed to understanding the great
metabolic variations existing in human beings. Phenotypic and
genotypic differences in the expression of the enzymes involved in
drug metabolism are the main causes of this variability. It is well
documented that P450 enzymes are polymorphically expressed (59,
64, 65). Mutations of P450 genes result in allelic variants causing
defective, qualitatively altered, diminished or enhanced rates of drug
metabolism. As a consequence, polymorphisms can lead to
qualitative and/or quantitative alterations in the metabolism of drugs
and could be responsible for the development of a number of
unexpected adverse drug reactions and host-specific susceptibility to
drugs or other chemicals. An association between polymorphisms
and increased toxicity risk or cancer has been reported (66). Among
P450 polymorphisms, those affecting CYP2C9, CYP2C19 and,
particularly CYP2D6, have the highest impact on drug metabolism
(67, 68). At present, a high number of CYP2D6 allelic variants (ca.
50) have been identified, some resulting in appreciable changes in
enzyme function. In contrast, CYP1A1, CYP2E1 and CYP3A4 genes
are relatively well conserved and only a few, if any, rare variants
yielding changes in catalytic enzyme activity have been found (65).
Interindividual differences in catalytic activities cannot be
exclusively attributed to genetic polymorphisms, and non-genetic
factors should be considered as a leading cause of the great
variability existing in drug metabolism rates. Age, gender, hormonal
status, liver pathologies and drug intake can influence the P450
function. CYP3A4, the most abundant P450 in the human liver,
constitutes a good example of phenotypic variability. Variations in
CYP3A4 activity cannot be explained by the genotype as only rare
allelic variants with no major functional effects have been identified
(69). CYP3A4 variability is probably a direct consequence of the
modulation of gene expression by environmental factors. The enzyme
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is highly induced by different groups of compounds, including
therapeutic agents such as glucocorticoids, antibiotics,
anticonvulsants, or anti-inflammatories (14, 70-72).
The use of in vitro models able to reflect interindividual variations
in drug metabolism will notably increase the relevance of preclinical
metabolic studies. The analysis of P450 enzymes in microsomes from
a human liver bank revealed the existence of considerable variability
(73). As an example, high variations (>50-fold) were found in CYP3A4
activity levels in microsome preparations form 30 different livers
(Figure 5A). A similar picture is observed when CYP3A4 activity is
measured in primary human hepatocyte cultures prepared from
different donors (Figure 5B). Incubation of the compound of interest
with human liver microsomes or hepatocytes expressing different
levels of P450 enzymes will help to anticipate information on
FIGURE 5. Variability of CYP3A4 activity in human liver and human
hepatocytes from different donors. CYP3A4 activity (testosterone
6β-hydroxylation) was determined (A) in microsomes from a human liver bank
(n = 30), and (B) in different preparations of human hepatocytes. The individual
data for CYP3A4 activity are plotted and sorted in decreasing order to show
inter-individual variability.
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potential interindividual variations in metabolic rates or metabolite
profile. The utility of cultured hepatocytes for this purpose was
examined by investigating the metabolism of a model compound,
aceclofenac, both in vitro and in vivo. The in vitro metabolism of the
compound was studied in hepatocyte cultures obtained from human
patients who, after clinical recovery, received a sub-clinical dose of
the drug to examine the metabolism in vivo (presence of metabolites
in urine) (74). A remarkable similarity between metabolic profile
and the extent of aceclofenac in vitro and in vivo metabolism was
found for each donor. These results support the idea that cultured
human hepatocytes are a good approximation to anticipate in vivo
metabolic profile of a drug, and back the validation process needed
by this experimental model to be considered as a simplified tool
to study drug metabolism and drug interactions. Moreover, the
interindividual variations in drug metabolism also become evident
in in vitro studies.
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